广济药业(000952) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥148,487,959.52, a decrease of 17.58% compared to ¥180,161,008.71 in the same period last year[5] - The net loss attributable to shareholders was ¥36,266,158.34, an improvement of 28.20% from a loss of ¥50,508,221.70 in the previous year[5] - The company reported a significant decrease in operating costs, which fell by 29.98% to ¥105,498,174.52, mainly due to lower sales volumes[10] - Net profit for the period was a loss of ¥40,179,691.10, compared to a loss of ¥54,669,434.50 in the previous period, indicating an improvement of approximately 26.5%[22] - The total comprehensive income for the period was -40,179,608.36 yuan, compared to -54,673,971.69 yuan in the previous period[23] - Basic and diluted earnings per share were both -0.1037 yuan, an improvement from -0.1427 yuan in the previous period[23] Cash Flow - The net cash flow from operating activities improved significantly to -¥584,644.24, a 98.79% increase compared to -¥48,243,051.48 in the same period last year[5] - Cash inflow from operating activities totaled 164,176,256.62 yuan, down from 281,576,516.95 yuan in the previous period[24] - Cash outflow from operating activities was 164,760,900.86 yuan, compared to 329,819,568.43 yuan in the previous period[25] - Net cash flow from investing activities was 37,259,004.87 yuan, compared to -26,527,939.59 yuan in the previous period[25] - Net cash flow from financing activities was 78,102,421.74 yuan, an increase from 62,815,258.68 yuan in the previous period[25] - The ending cash and cash equivalents balance was 422,361,332.62 yuan, up from 403,741,511.20 yuan in the previous period[25] Assets and Liabilities - Total assets increased by 3.57% to ¥2,893,357,332.63 from ¥2,793,578,628.65 at the end of the previous year[5] - Current liabilities rose to ¥1,133,129,466.25 from ¥927,514,498.99, an increase of approximately 22.2%[19] - Non-current liabilities decreased to ¥723,975,555.91 from ¥789,867,879.44, a decline of about 8.4%[19] - The company's total equity attributable to shareholders decreased by 3.39% to ¥1,028,882,808.00 from ¥1,064,939,987.31 at the end of the previous year[5] - The company's total equity decreased to ¥1,036,252,310.47 from ¥1,076,196,250.22, a decrease of approximately 3.7%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,038, with no preferred shareholders having restored voting rights[13] - The largest shareholder, Changjiang Industrial Investment Group, holds 25.04% of shares, totaling 87,592,065 shares[13] - The company has no preferred shareholders and no significant changes in the top ten shareholders' participation in margin trading[14] - The company has not identified any related party relationships among the top ten shareholders, except for Changjiang Industrial Investment Group[13] - The company did not undergo an audit for the first quarter report[26] Capital and Investment - The company plans to raise capital through public listing for its wholly-owned subsidiary, Hubei Guanghua Pharmaceutical Co., Ltd., with a new registered capital of RMB 250 million[14] - Two strategic investors have been identified for the capital increase, with investments of RMB 200 million and RMB 50 million respectively[15] - The company has not utilized its preemptive rights in the capital increase process for its subsidiary[14] - The company will no longer consolidate Hubei Guanghua Pharmaceutical into its financial statements after the capital increase[14] Research and Development - Research and development expenses decreased by 32.22% to ¥10,910,609.64, attributed to reduced investment in R&D projects during the reporting period[10] - Research and development expenses decreased to ¥10,910,609.64 from ¥16,095,943.13, a reduction of about 32.3% year-over-year[22] Other Financial Metrics - Cash and cash equivalents rose by 37.50% to ¥422,361,332.62, primarily due to increased cash flow from investment and operating activities[8] - The company reported a significant increase in other payables, rising to ¥137,256,241.36 from ¥80,524,801.45, an increase of approximately 70.3%[19] - Accounts receivable decreased to RMB 168,273,997.44 from RMB 174,029,671.89[17]